• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.

作者信息

Lu Jialing, Bao Xiebing, Zhou Jihao, Li Xiaoli, He Zhewei, Ji Yujie, Xue Shengli, Chen Suning, Wu Depei, Hu Qi, Ke Peng, Ma Xiao

机构信息

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

Blood Cancer J. 2024 Aug 23;14(1):143. doi: 10.1038/s41408-024-01127-2.

DOI:10.1038/s41408-024-01127-2
PMID:39179531
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11344091/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19e0/11344091/1060c24fc67b/41408_2024_1127_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19e0/11344091/1060c24fc67b/41408_2024_1127_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19e0/11344091/1060c24fc67b/41408_2024_1127_Fig1_HTML.jpg

相似文献

1
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.在首次完全缓解且无可检测微量残留病的B细胞急性淋巴细胞白血病患者中，blinatumomab作为移植桥接治疗的安全性和有效性。
Blood Cancer J. 2024 Aug 23;14(1):143. doi: 10.1038/s41408-024-01127-2.
2
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.儿童移植后复发/难治性B前体急性淋巴细胞白血病通过使用T细胞接合双特异性抗体博纳吐单抗治疗显示出持久缓解。
Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.
3
Safety and efficacy of blinatumomab: a real world data.真实世界数据评估blinatumomab 的安全性和疗效。
Ann Hematol. 2020 Apr;99(4):835-838. doi: 10.1007/s00277-019-03854-0. Epub 2020 Feb 20.
4
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.在接受博纳吐单抗治疗后达到微小残留病（MRD）缓解的复发/难治性急性淋巴细胞白血病（ALL）患者中的长期生存和T细胞动力学
Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.
5
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效：一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
6
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.FDA 批准：blinatumomab 用于伴有微小残留病灶的形态学缓解的 B 细胞前体急性淋巴细胞白血病患者。
Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25.
7
Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.blinatumomab 作为复发/难治性 B 细胞前体急性淋巴细胞白血病成人患者的一线挽救治疗与二线或更后线挽救治疗的比较：一项汇总分析结果。
Cancer Med. 2021 Apr;10(8):2601-2610. doi: 10.1002/cam4.3731. Epub 2021 Mar 18.
8
Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.blinatumomab 对比化疗用于 B 细胞前体急性淋巴细胞白血病的一线挽救治疗或二线挽救治疗。
Leuk Lymphoma. 2019 Sep;60(9):2214-2222. doi: 10.1080/10428194.2019.1576872. Epub 2019 Apr 5.
9
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.针对化疗耐药的 B 系急性淋巴细胞白血病患者微小残留病灶的 T 细胞结合抗体blinatumomab 的靶向治疗可带来高缓解率和延长无白血病生存。
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
10
Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.博纳吐单抗作为异基因造血细胞移植后B系急性淋巴细胞白血病/淋巴瘤维持治疗的疗效
Blood Cancer J. 2024 Jul 8;14(1):109. doi: 10.1038/s41408-024-01092-w.

引用本文的文献

1
Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.嵌合抗原受体T细胞（CAR-T）免疫疗法与博纳吐单抗免疫疗法作为复发/难治性B细胞急性淋巴细胞白血病桥接移植策略的疗效与安全性比较
J Transl Med. 2025 Apr 3;23(1):391. doi: 10.1186/s12967-025-06399-1.
2
Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know.通过可测量残留病确定的急性白血病患者的干细胞移植指征：我们已知和未知的情况。
Blood Sci. 2025 Mar 25;7(2):e00229. doi: 10.1097/BS9.0000000000000229. eCollection 2025 Jun.

本文引用的文献

1
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.Blinatumomab 治疗成人 MRD 阴性急性淋巴细胞白血病。
N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.
2
Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation.移植前blinatumomab 改善接受异基因造血细胞移植的 B 细胞急性淋巴细胞白血病患者的结局。
Transplant Cell Ther. 2024 May;30(5):520.e1-520.e12. doi: 10.1016/j.jtct.2024.03.004. Epub 2024 Mar 8.
3
The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
下一代测序检测到的儿童 B 细胞急性淋巴细胞白血病患者中blinatumomab 清除可测量残留病的疗效。
Cancer Med. 2023 Dec;12(24):21978-21984. doi: 10.1002/cam4.6771. Epub 2023 Dec 8.
4
Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.Blinatumomab 治疗与儿童 B 细胞急性淋巴细胞白血病患者异基因造血细胞移植后的良好结局相关。
Transplant Cell Ther. 2024 Feb;30(2):217-227. doi: 10.1016/j.jtct.2023.10.024. Epub 2023 Nov 4.
5
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.在达到完全缓解且微小残留病灶不可检测的成人 B 细胞急性淋巴细胞白血病患者中，异体或自体造血干细胞移植后接受维持化疗的结果。
Br J Haematol. 2023 Jul;202(2):369-378. doi: 10.1111/bjh.18846. Epub 2023 May 8.
6
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.成人急性淋巴细胞白血病强化治疗：GRAALL-2005 临床试验的随机报告。
J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4.
7
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.Blinatumomab 治疗 B 细胞前体急性淋巴细胞白血病成人患者的微小残留病。
Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
8
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.微小残留病与儿童及成人急性淋巴细胞白血病临床结局的相关性：一项荟萃分析。
JAMA Oncol. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580.
9
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.博纳吐单抗对比化疗治疗晚期急性淋巴细胞白血病
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
10
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.酪氨酸激酶抑制剂可改善费城染色体阳性成人急性淋巴细胞白血病患者异基因造血干细胞移植的长期疗效。
Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.